Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer

Femme Homme

| Pays :
| Organes :
| Spécialités :

Extrait

Determination of the safety of an adjuvant treatment with catumaxomab in patients with epithelial ovarian cancer in terms of post-operative complication rate.

Critère d'inclusion

Epithelial Ovarian Cancer

Liens

euctr
ictrp
ictrp
euctr